This trial is active, not recruiting.

Conditions acute coronary syndrome, non-st elevation (nstemi) myocardial infarction, acute st segment elevation myocardial infarction, angina, unstable
Treatment oxygen
Phase phase 3
Sponsor Karolinska Institutet
Collaborator Swedish Heart Lung Foundation
Start date April 2013
End date March 2017
Trial size 6650 participants
Trial identifier NCT01787110, DETO2X-AMI 2012/287-12


The use of supplemental oxygen in the setting of suspected acute myocardial infarction (AMI) is manifested in international treatment guidelines and established in prehospital and hospital clinical routine throughout the world.

However, to date there is no conclusive evidence from adequately designed and powered trials supporting this practice. Existing data is conflicting and failing to clarify the role of supplemental oxygen in AMI.

The DETO2X-AMI trial is designed to shed light on this important issue.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose treatment
Masking no masking
(No Intervention)
For patients randomised to withholding oxygen treatment no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed) all patients receive standard acute coronary syndrome treatment including reperfusion strategies observation duration 12 hours
(Active Comparator)
For patients randomised to oxygen therapy: 6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours) all patients receive standard acute coronary syndrome treatment including reperfusion strategies
see arm description

Primary Outcomes

1-year all-cause mortality
time frame: 1 year

Secondary Outcomes

time frame: 1 year
time frame: 1 year
time frame: 1 year
Rehospitalization with heart failure
time frame: 1 year
Rehospitalization with AMI
time frame: 1 year
Rehospitalization with shock (Killip ≥3)
time frame: 1 year
Cardiovascular death
time frame: 1 year
Health economics
time frame: 1 year

Eligibility Criteria

All participants at least 30 years old.

Inclusion Criteria: - symptoms (chest pain, dyspnea) indicating acute myocardial ischemia within the last 6 hours - ECG changes (ST-segment elevation ≥ 2 mm V1-V4, or ≥ 1 mm in other leads, ST-segment depression >1 mm in any lead, negative T-wave in leads V2-V6, pathological Q-wave in at least 2 adjacent leads), left bundle branch block and/or elevated levels of cardiac troponin levels in the ED indicating acute myocardial ischemia - oxygen saturation ≥90% (pulse oximeter) - age ≥30 Exclusion Criteria: - unwillingness to participate - inability to comprehend given information - continuous oxygen delivery at home prior to inclusion - cardiac arrest prior to inclusion

Additional Information

Official title DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry
Description AIM: The aim of the DETO2X-AMI trial is to evaluate the role of supplemental oxygen delivery in the setting of acute coronary syndrome myocardial infarction including ST-segment elevation myocardial infarction (STEMI), non ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA). DESIGN: DETO2X-AMI is a multicentre, interventional, controlled, randomized registry based clinical trial (RRCT) recruiting 6600 patients at cardiac care facilities which report into the SWEDEHEART registry throughout the whole of Sweden. The SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry is a nationwide used platform allowing a broad population of all-comers access to the broad registry network which includes: - RIKS-HIA (nationwide registry where all ischemia cases treated on cardiac intensive care units are registered), - SCAAR (Swedish Coronary Angiography and Angioplasty Registry where nationwide all coronary angiography and percutaneous coronary intervention (PCI) procedures are registered)) - SEPHIA (nationwide registry for all post AMI follow-up in patients below 75 years of age). All follow-up will be carried out in SWEDEHEART and other national registries such as the national cause of death register (dödsorsaksregister) or the national patient register (slutenvårdsregister). A similar set-up has been successfully used for the TASTE (Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia) trial. MATERIAL and METHODS: Patients with normal oxygen saturation (≥90% on pulse oximeter) presenting to the ambulance service or the emergency department (ED) with classical symptoms suggestive of acute coronary syndrome (ACS) and significant ECG changes or elevated cardiac biomarkers (ED) are evaluated for inclusion. If eligible, oral informed consent is obtained by EMD or ED personnel prior to inclusion. Randomization is carried out on the cardiac intensive care unit using a web-based tool as part of registration directly into the national SWEDEHEART registry. Patients are randomized to either supplemental oxygen delivered by oxymask® (6 L/min) for 12 hours (min 6 hours) or no supplemental O₂. All patients receive standard care according to international ACS guidelines including acute coronary intervention. EFFICACY OUTCOMES: Primary efficacy outcome All-cause mortality at one year in all patients with suspected AMI (ITT). Secondary efficacy outcomes In the ITT population and AMI cohort: - MACE 1: composite of all-cause mortality or rehospitalization with heart failure* - MACE 2: composite of all-cause mortality or rehospitalization with heart failure or readmission with myocardial infarction - rehospitalization with heart failure - rehospitalization with AMI - rehospitalization with shock (Kilip ≥3)* - cardiovascular death * - health economy In the STEMI cohort: MACE as a composite of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis* plus as above. *These outcomes were specified after the trial had started, but before any treatment comparisons were available. Primary and secondary outcomes will be assessed at 30 days and one year of follow up. Supplementary per-protocol analysis will be performed. Subgroup analyses consist of predefined subgroups including gender, age, AMI/Non-AMI, Type-I AMI ( STEMI/NSTEMI), smokers, Hb, oxygen saturation levels, patients with chronic obstructive pulmonary disease, chronic kidney disease and diabetes mellitus. Two main sub studies will be performed: DETO2X-Biomarkers, a multicenter sub study to the DETO2X-AMI trial assessing if oxygen treatment enhances oxidative stress, systemic inflammation, and markers of apoptosis and MMPs in ACS patients, thereby potentially increasing myocardial damage and cell death, and potentially the prognosis (see separate trial protocol or clinicaltrials.gov NCT02290080 for details). DETO2X-OXYPAIN 2, a multicenter sub study to the DETO2X-AMI trial at centers with catheter laboratories evaluating a possible analgesic effect of oxygen in using visual-analog scale (VAS). Follow-up is carried out according to clinical post AMI routine which includes a standardized registration in the SWEDEHEART registry. Mortality data is obtained from the national cause of death register which is linked to SWEDEHEART. CONCLUSION: There is no conclusive evidence from adequately designed and powered trials supporting the routine administration of supplemental oxygen in the setting of suspected AMI. The DETO2X-AMI trial is designed to shed light on this important issue and give guidance to future recommendations.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Karolinska Institutet.